January 07, 2024

We welcome Dr David Bearss to our strategic advisory board

We are pleased to announce the induction of David Bearss Ph.D. to our strategic advisory board as a key advisor for clinical trials.

Dr. David Bearss is the CEO of Halia Therapeutics, Inc. He is an experienced entrepreneur and drug developer with 20 plus years of experience in academic and industry settings.

We are confident that Dr. Bearss’ comprehensive understanding of the drug development life cycle and technical expertise in all aspects of patient care will add immeasurable value to our Customer’s Clinical Development Plans.

CBCC Global Research: CHANGING LIVES THROUGH HOPE AND INNOVATION

We welcome Dr David Bearss to our strategic advisory board